Results 161 to 170 of about 140,911 (217)

Moderate-intensity statin plus ezetimibe as an alternative to high-intensity statin therapy. [PDF]

Cardiovasc Diabetol
Albawa'neh AS, Ali BR.
europepmc   +1 more source

Association Between SGLT2 Inhibitors and DPP‐4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case‐Based Analyses

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The Korean national health insurance claims database was utilised to investigate the association between sodium–glucose cotransporter 2 inhibitors (SGLT2i) or dipeptidyl peptidase‐4 inhibitors (DPP‐4i) and the risk of acute pancreatitis (AP). Materials and Methods Patients with type 2 diabetes mellitus prescribed DPP‐4i or SGLT2i at least
Ye‐Jee Kim, Yun Kyung Cho, Mi‐Sook Kim, Joongyub Lee, Seonghae Kim, Bo Ram Yang   +5 more
wiley   +1 more source

The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Pharmacokinetic data suggest a potential dose‐dependent effect of sodium–glucose co‐transporter‐2 (SGLT‐2) inhibitors on surrogate markers of efficacy, but the impact of SGLT‐2 inhibitor dose on renal and cardiovascular outcomes remains uncertain.
Elias John Elenjickal, Frédéric Baroz, Philippe Boileau, Michael A. Tsoukas, Abhinav Sharma, Thomas A. Mavrakanas   +5 more
wiley   +1 more source

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano, Line L. Haurum, Christine R. Schwarz, Francesca Porcellati, Andreas Andersen   +4 more
wiley   +1 more source

Statin Therapy Protects White Matter in Cerebral Small Vessel Disease Independent of Lipid-Lowering: Biomarker and Neuroimaging Evidence. [PDF]

Brain Behav
Wang R, Chen J, Ma P, Liu L, Wang Y, Tang Q.   +5 more
europepmc   +1 more source

Cardiovascular Outcomes in a SELECT‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger, Josefine Fagerström, Håkan Nero, Thomas Cars, Maria K. Svensson, Anna Norhammar   +5 more
wiley   +1 more source

Age trumps metabolism: No independent association between lipids, statins, and prostate enlargement in a metabolically controlled cohort. [PDF]

Clinics (Sao Paulo)
Oliveira LN, Tiraboschi RB, Silva CS, Santos JB, Oliveira MN, Gomes CM, Bessa Junior J.   +6 more
europepmc   +1 more source

Proteomic Profiling Captures Residual Cardiovascular Risk Beyond the PREVENT Model in Individuals With Cardiovascular–Kidney–Metabolic Syndrome Stages 2–3

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Cardiovascular–kidney–metabolic (CKM) syndrome reflects complex pathobiological interactions among metabolic disorders, kidney injury, and cardiovascular disease (CVD). Stages 2 and 3 represent critical phases of disease progression characterised by high pathological heterogeneity.
Xuefei Han, Jiacheng Ding, Jingqian Li, Yiyin Gao, Yunqian Li   +4 more
wiley   +1 more source

Lipid-lowering therapy for primary prevention of cardiovascular disease in adults aged 75 years and older: a narrative review. [PDF]

Int J Cardiol Cardiovasc Risk Prev
Stephan D, Zamperini C, Cordeanu EM.
europepmc   +1 more source